Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119920 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
A Phase 2 study of Dry Eye Disease and Keratoconjunctivitis Sicca, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
- 19
- Study locations
NCT05119920: Completed Phase 2 study of Dry Eye Disease and Keratoconjunctivitis Sicca, sponsored by Glaukos Corporation.
NCT05119920 is a Phase 2 study of Dry Eye Disease and Keratoconjunctivitis Sicca that has completed, run by Glaukos Corporation. The registered enrollment target is 226 participants, roughly in line with the 248-participant average among 33 other Dry Eye Disease trials with a reported enrollment target. The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05119920, a Phase 2 study of Dry Eye Disease and Keratoconjunctivitis Sicca, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye Disease.
Primary Outcome
Mean change from baseline in the VAS score at Day 28 visit. Visual Analogue Scale from 0 (no discomfort) to 100 (maximal discomfort)
Conditions Studied
Interventions
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 1
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 2
- DRUG Pilocarpine Ophthalmic Topical Cream, Dose 3
- DRUG Placebo Ophthalmic Topical Cream
Study Locations (19)
California
- Glaukos Investigator - Glendale
- Glaukos Investigator - Mission Hills
- Glaukos Investigator - Newport Beach
- Glaukos Investigator - Petaluma
- Glaukos Investigator - Rancho Cordova
Arizona
- Glaukos Investigator - Chandler
- Glaukos Investigator - Sun City
Tennessee
- Glaukos Investigator - Memphis
- Glaukos Investigator - Nashville
Texas
- Glaukos Investigator - Houston
- Glaukos Investigator - San Antonio
Colorado
- Glaukos Investigator - Grand Junction
Florida
- Glaukos Investigator - Fort Myers
Georgia
- Glaukos Investigator - Roswell
Missouri
- Glaukos Investigator - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2022-01-03 |
| Est. Completion | 2022-07-27 |
| Phase | Phase 2 |
What the finished NCT05119920 record still lists
NCT05119920 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 248-participant average among 33 other Dry Eye Disease trials with a reported enrollment target.
The record links to 2 conditions, with Dry Eye Disease appearing as the primary indexed condition, and to 4 interventions - of which Pilocarpine Ophthalmic Topical Cream, Dose 1 is the first listed.
NCT05119920 lists 19 locations in 12 states (California, Arizona, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05119920 about?
NCT05119920 is a clinical study titled "Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease". This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye Disease.
What is the current status of trial NCT05119920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2022-01-03. Estimated completion is 2022-07-27.
What conditions does trial NCT05119920 study?
This clinical trial studies the following conditions: Dry Eye Disease, Keratoconjunctivitis Sicca.
What interventions are being tested in trial NCT05119920?
The interventions under investigation include: Pilocarpine Ophthalmic Topical Cream, Dose 1 (DRUG), Pilocarpine Ophthalmic Topical Cream, Dose 2 (DRUG), Pilocarpine Ophthalmic Topical Cream, Dose 3 (DRUG), Placebo Ophthalmic Topical Cream (DRUG).
Who is sponsoring clinical trial NCT05119920?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05119920 being conducted?
This trial has 19 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05119920's enrollment target sits among peer trials
226 15th of 33 higher than 19 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI